伊马替尼
医学
治疗药物监测
药品
甲磺酸伊马替尼
间质细胞
药理学
肿瘤科
内科学
髓系白血病
作者
Wan‐Ting Huang,Juan Li,Feng Qiu,Xingye Wu,Jun Zhang,Xuemei Li,Gaoqiong Yao,Shaowei Zhu
摘要
What is known and objective Imatinib mesylate (IM) is the first-line therapy for unresectable or metastatic gastrointestinal stromal tumours (GISTs). Here, we report a case of successful progressive dose optimization by therapeutic drug monitoring (TDM) for a patient with GISTs who developed IM-associated serious cutaneous reactions. Case description A 72-year-old female patient received IM at a dose of 400 mg/day for GISTs. The patient developed serious eczematoid drug eruptions and desquamation, following which IM was discontinued. One year later, the GISTs recurred with metastasis, and IM was re-administered at a dose of 100 mg/day, and the dose was gradually increased on the basis of TDM. The final dose of IM was 200 mg/day, and the trough concentration (Ctrough) of IM was 1457.76 ng/mL. The images obtained from follow-up computed tomography (CT) showed a marked anti-tumour response. IM was well tolerated and the patient developed tolerable IM-associated cutaneous reactions. What is new and conclusion The strategy of TDM-guided dose optimization makes it possible to achieve optimal clinical efficacy for patients with GISTs who develop IM-associated serious cutaneous reactions.
科研通智能强力驱动
Strongly Powered by AbleSci AI